Evidence map›Paper›PMID 34644317›Full record

Trial reportPloS one2021

Impact of mass administration of azithromycin as a preventive treatment on the prevalence and resistance of nasopharyngeal carriage of Staphylococcus aureus.

Soumeya Hema-Ouangraoua, Juliette Tranchot-Diallo, Issaka Zongo, Nongodo Firmin Kabore, Frédéric Nikièma, Rakiswende Serge Yerbanga, Halidou Tinto, Daniel Chandramohan, Georges-Anicet Ouedraogo, Brian Greenwood and 1 more

Open access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Life (Basel, Switzerland) · 2023
    Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Soumeya Hema-OuangraouaCentre MURAZ, Bobo-Dioulasso, Burkina Faso.ORCID 0000-0003-2960-1873
Juliette Tranchot-DialloCentre MURAZ, Bobo-Dioulasso, Burkina Faso.
Issaka ZongoInstitut de Recherche en Sciences de la Santé (IRSS), Direction Régionale de l'Ouest (DRO), Bobo-Dioulasso, Burkina Faso.
Nongodo Firmin KaboreCentre MURAZ, Bobo-Dioulasso, Burkina Faso.
Frédéric NikièmaInstitut de Recherche en Sciences de la Santé (IRSS), Direction Régionale de l'Ouest (DRO), Bobo-Dioulasso, Burkina Faso.
Rakiswende Serge YerbangaInstitut de Recherche en Sciences de la Santé (IRSS), Direction Régionale de l'Ouest (DRO), Bobo-Dioulasso, Burkina Faso.
Halidou TintoInstitut de Recherche en Sciences de la Santé (IRSS), Direction Régionale de l'Ouest (DRO), Bobo-Dioulasso, Burkina Faso.
Daniel ChandramohanLondon School of Hygiene & Tropical Medicine, London, United Kingdom.
Georges-Anicet OuedraogoUniversité Nazi Boni, Bobo-Dioulasso, Burkina Faso.
Brian GreenwoodLondon School of Hygiene & Tropical Medicine, London, United Kingdom.
Jean-Bosco OuedraogoInstitut de Recherche en Sciences de la Santé (IRSS), Direction Régionale de l'Ouest (DRO), Bobo-Dioulasso, Burkina Faso.
Institut de Recherche en Sciences de la Santé · BFCentre Muraz · BFLondon School of Hygiene & Tropical Medicine · GBNazi Boni University · BF

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Staphylococcus aureus is a major cause of serious illness and death in children, indicating the need to monitor prevalent strains, particularly in the vulnerable pediatric population. Nasal carriage of S. aureus is important as carriers have an increased risk of serious illness due to systemic invasion by this pathogen and can transmit the infection. Recent studies have demonstrated the effectiveness of azithromycin in reducing the prevalence of nasopharyngeal carrying of pneumococci, which are often implicated in respiratory infections in children. However, very few studies of the impact of azithromycin on staphylococci have been undertaken. During a clinical trial under taken in 2016, nasal swabs were collected from 778 children aged 3 to 59 months including 385 children who were swabbed before administration of azithromycin or placebo and 393 after administration of azithromycin or placebo. Azithromycin was given in a dose of 100 mg for three days, together with the antimalarials sulfadoxine-pyrimethamine and amodiaquine, on four occasions at monthly intervals during the malaria transmission season. These samples were cultured for S. aureus as well as for the pneumococcus. The S. aureus isolates were tested for their susceptibility to azithromycin (15 g), penicillin (10 IU), and cefoxitine (30 g) (Oxoid Ltd). S. aureus was isolated from 13.77% (53/385) swabs before administration of azithromycin and from 20.10% (79/393) six months after administration (PR = 1.46 [1.06; 2.01], p = 0.020). Azithromycin resistance found in isolates of S. aureus did not differ significantly before and after intervention (26.42% [14/53] vs 16.46% [13/79], (PR = 0.62 [0.32; 1.23], p = 0.172). Penicillin resistance was very pronounced, 88.68% and 96.20% in pre-intervention and in post-intervention isolates respectively, but very little Methicillin Resistance (MRSA) was detected (2 cases before and 2 cases after intervention). Monitoring antibiotic resistance in S. aureus and other bacteria is especially important in Burkina Faso due to unregulated consumption of antibiotics putting children and others at risk.

Indexed as

Anti-Bacterial AgentsAntimalarialsAzithromycinChild, PreschoolDrug Resistance, BacterialFemaleHumansInfantMalariaMaleNasopharynxPrevalenceStaphylococcal InfectionsStaphylococcus aureusAnti-Bacterial AgentsAntimalarialsAzithromycin

Identifiers

PMID34644317
PMCPMC8513893
OpenAlexW3206502360

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.